What changed in Amgen Inc.'s latest annual report
In the year ended 31 Dec 2025, Amgen Inc.'s revenue rose 10% to USD 36.75bn, from USD 33.42bn; net income rose 88.5% to USD 7.71bn, from USD 4.09bn; shareholders' equity rose 47.3% to USD 8.66bn, from USD 5.88bn.
Year ended 31 Dec 2025. Source: 10-K filed 13 Feb 2026, read it on SEC EDGAR.
USD 33.42bn to USD 36.75bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 33.42bn | 36.75bn | Up 10% |
| Net income | 4.09bn | 7.71bn | Up 88.5% |
| Total assets | 91.84bn | 90.59bn | Down 1.4% |
| Long-term debt | 56.55bn | 50.01bn | Down 11.6% |
| Cash and cash equivalents | 11.97bn | 9.13bn | Down 23.8% |
| Shareholders' equity | 5.88bn | 8.66bn | Up 47.3% |
Questions people ask
Did Amgen Inc.'s revenue grow last year?
Revenue grew 10%, from USD 33.42bn to USD 36.75bn in the year ended 31 Dec 2025.
Is Amgen Inc. profitable?
Yes. Net income was USD 7.71bn in the year ended 31 Dec 2025. The year before: USD 4.09bn.
How much cash and debt does Amgen Inc. have?
At its latest year end (31 Dec 2025), Amgen Inc. reported cash and cash equivalents of USD 9.13bn and long-term debt of USD 50.01bn.
Where do these numbers come from?
From Amgen Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Amgen Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%
- Repligen CorpCash and cash equivalents down 25.3%